ATTO vs RIGL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ATTO · Attovia Therapeutics$15.10 ▼ 3.08%
RIGL · Rigel Pharmaceuticals$40.09 ▼ 2.67%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ATTO -31.1%
- RIGL -1.0%
Head to head
| Metric | ATTO | RIGL |
|---|---|---|
| Price | $15.10 | $40.09 |
| Change today | ▼ 3.08% | ▼ 2.67% |
| Market cap | $690.26M | $754.89M |
| Return, 3 months | -26.8% | -11.1% |
| Return, year to date | – | -6.4% |
| Return, 1 year | – | -13.3% |
| P/E (TTM) | – | 2.5 |
| P/B | 1.7 | 1.7 |
| P/E percentile vs own 5y | 94th | 70th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -100.0% | +16.5% |
| Net profit growth (YoY) | -61.6% | -52.7% |
| Gross margin | – | 89.6% |
| Operating margin | -5,945.5% | 26.3% |
| Net margin | -5,477.2% | 106.6% |
| Return on equity | -19.8% | 109.2% |
| Analyst target vs. price | +171.5% | +66.5% |
| Analyst buy share | 100% | 50% |
| RSI (14) | 45 | 35 |
| 30-day volatility | 62.6% | 66.4% |
| Max drawdown, 1 year | -46.3% | -50.1% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- RIGL is the largest of the group by market value.
- RIGL is growing revenue fastest.
- RIGL keeps the most profit per dollar of sales.
- ATTO has been the calmest stock over the last 30 days.